Biologics/ biopharmaceuticals like insulin, monoclonal antibodies are the products obtained from living entities such as cells, tissues, organisms or sophisticated techniques like RNDA technology. Biosimilars are similar to reference biological product in terms of safety, efficacy, quality and purity. They are not ‘biogeneric'. Biosimilars provide access to affordable advanced medicines to people in developing countries. Use of biosimilars is expected to save cost on healthcare in US by $40 to $250 billion over 10 years.
Biosimilar market is projected to grow from 4-6 billion dollars in 2016 to 25-35 billion dollars by 2020. ̴ 450 biosimilars are being developed & ̴250 are in pipeline globally. Although biosimilars received a rather cool welcome from the innovative side of the business, several innovators have entered the market over the last few years. Approval of biosimilars…
